The COVID-19 impact on severe uncontrolled asthma costs and biologic use.

Patients with severe uncontrolled asthma (SUA) overwhelmingly contribute to the economic burden of asthma and may require biologic therapy. However, the impact of the CoronaVirus Disease of 2019 (COVID-19) on asthma costs and biologic use has yet to be evaluated. The objective was to test the hypothesis that SUA costs and biologic use decreased during the pandemic.

Biomarker underuse contributes to an inability to phenotype patients with severe uncontrolled asthma.

Biomarker measurements improve the phenotyping of patients with severe uncontrolled asthma (SUA) and predict therapeutic responses. The use of biomarkers in asthma, however, remains underused. To test the hypothesis that biomarker measurements of patients with SUA remain markedly underused and contributes to asthma morbidity and oral corticosteroid use.